ZVRA Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
39.7M
+9.5%
36.2M
+6.1%
34.1M
+30.9%
26.1M
+0.7%
25.9M
Cost of Revenue
1.5M
-19.6%
1.9M
+24.8%
1.5M
+22.8%
1.2M
-90.0%
12.4M
Gross Profit
38.1M
+11.1%
34.3M
+5.3%
32.6M
+31.3%
24.8M
+83.9%
13.5M
Operating Expenses
21.4M
-16.2%
25.5M
+9.5%
23.3M
+12.6%
20.7M
-75.5%
84.5M
R&D
4.5M
+2.1%
4.4M
+67.6%
2.6M
-23.7%
3.4M
-0.0%
3.4M
SG&A
16.6M
-20.3%
20.8M
+2.1%
20.4M
+20.2%
16.9M
-18.5%
20.8M
Operating Income
16.8M
+90.0%
8.8M
-5.2%
9.3M
+124.8%
4.1M
+105.8%
-71039000
EBITDA
17.1M
+86.3%
9.2M
+118.8%
-49033000
-177.5%
63.2M
+692.3%
-10678000
Net Income
8.8M
-76.9%
37.9M
+211.5%
12.2M
+2336.2%
-544000
-100.7%
74.7M
EPS (Basic)
$0.14
-77.4%
$0.62
+181.8%
$0.22
+2300.0%
$-0.01
-100.8%
$1.24
EPS (Diluted)
$0.14
-76.7%
$0.60
+215.8%
$0.19
+2000.0%
$-0.01
-100.8%
$1.21
Shares (Diluted)
61.3M
+1.8%
60.2M
-3.9%
62.7M
+12.0%
56.0M
-0.7%
56.3M
Zevra Therapeutics (ZVRA) โ€” Financials